fbpx

Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy

This randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the safety and efficacy of two-weeks of nightly sublingual cannabinoid extract (ZTL-101) in treating chronic insomnia (symptoms ≥three months).

The post Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy appeared first on Society of Cannabis Clinicians.

Leave a Reply

Generated by Feedzy
%d bloggers like this: